» Articles » PMID: 20373422

Multiparametric Assessment of the Anti-glioma Properties of OKN007 by Magnetic Resonance Imaging

Overview
Date 2010 Apr 8
PMID 20373422
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To demonstrate that OKN007, a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), has anti-glioma activity in the clinically relevant C6 rat glioma model using multi-parametric magnetic resonance imaging.

Materials And Methods: Twenty-one rats were intracerebrally implanted with C6 cells and administered OKN007 or kept as controls. Animals were monitored with MRI at 7 Tesla (T), using morphologic, diffusion-weighted and perfusion imaging, followed by histology and Western blots of angiogenesis and inflammatory markers.

Results: OKN007 was found to decrease tumor volumes and increase survival. The glioma tissues of OKN007-treated rats were found to have longitudinal apparent diffusion coefficients (ADC(z)) of 0.76 +/- 0.06 x 10(-3) mm(2)/s, similar to the contralateral tissue and significantly smaller than untreated gliomas (0.97 +/- 0.13 x 10(-3) mm(2)/s). They had higher perfusion rates (66 +/- 4 mL/100 g.min) than untreated gliomas (26 +/- 7 mL/100 g.min). All examined molecular markers were decreased in OKN007-treated rat gliomas, compared with elevated levels in untreated rats.

Conclusion: MRI assessment was successfully used to monitor a decrease in tumor growth, and corresponding alterations in ADC and perfusion rates in rat C6 gliomas treated with the anti-glioma agent, OKN007.

Citing Articles

Integrative Magnetic Resonance Imaging and Metabolomic Characterization of a Glioblastoma Rat Model.

Arias-Ramos N, Vieira C, Perez-Carro R, Lopez-Larrubia P Brain Sci. 2024; 14(5).

PMID: 38790388 PMC: 11118082. DOI: 10.3390/brainsci14050409.


OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera.

Towner R, Hocker J, Smith N, Saunders D, Battiste J, Hanas J Brain Sci. 2022; 12(1).

PMID: 35053843 PMC: 8773900. DOI: 10.3390/brainsci12010100.


A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.

Zalles M, Smith N, Saunders D, Lerner M, Fung K, Battiste J J Cell Mol Med. 2021; 26(2):570-582.

PMID: 34910361 PMC: 8743651. DOI: 10.1111/jcmm.17133.


OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.

Thomas L, Smith N, Saunders D, Zalles M, Gulej R, Lerner M J Transl Med. 2020; 18(1):424.

PMID: 33168005 PMC: 7654606. DOI: 10.1186/s12967-020-02593-5.


Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.

Ziegler J, Zalles M, Smith N, Saunders D, Lerner M, Fung K Am J Nucl Med Mol Imaging. 2019; 9(1):93-109.

PMID: 30911439 PMC: 6420708.